Tuberculosis Drug
Tuberculosis Drug

Tuberculosis Drug Comprehensive Study by Type (First-line Anti-TB Drugs, Second-line Anti-TB Drugs), Application (Active TB, Latent TB), End User (Hospital, Clinic, Durgstore), Testing (TB skin test (TST), TB blood tests, Others) Players and Region - Global Market Outlook to 2026

Tuberculosis Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 232 Pages 177 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Tuberculosis Drug Market Overview:
Tuberculosis remains a global public health concern. According to the World Health Organization, in 2017, the annual incidence of Tuberculosis (TB) in India was 2.8 million cases, with an estimated 147,000 multi-drug resistant cases. India has the second highest estimation of HIV-TB co-infection 87,000 cases per year. The TB treatment drugs market is expected to witness high growth in the coming years due to development of shorter-regimen drug treatments and availability of private and public funding. About one third of the worlds's population is suffering with latent tuberculosis, people infected with mycobacterium infection have a 10% risk to fall ill with tuberculosis, however people with compromised immunity such as HIV, diabetes and tobacco addiction are at a higher risk to get tuberculosis. TB is second to HIV as it is the leading infectious killer of the adults worldwide. Apart from its health consequences, there are many economic impact of the disease which is staggering, making TB a major contributor to poverty. Some of the players profiled in the study are Johnson & Johnson (United States), Lupin Limited (India), Pfizer Inc. (United States), Eli Lilly and Company (United States), Labatec Pharma SA (Jordan), Mylan N.V (United States), Sanofi S.A (France), Sandoz S.A (Germany), Novartis International AG (India), Macleods Pharmaceuticals (India) and Otsuka Pharmaceutical Co.Ltd. (Japan).

On the basis of geography, the market of Tuberculosis Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospital will boost the Tuberculosis Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Testing, the sub-segment i.e. TB skin test (TST) will boost the Tuberculosis Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Prevalence of Tuberculosis
  • Government Initiatives to Control the Proliferation of Tuberculosis

Influencing Trend
  • Increasing Government and Non-government Initiatives i.e. DOTS to Eradicate Tuberculosis
  • Promising Pipeline for the Treatment of Tuberculosis.

Restraints
  • Lack of Awareness Regarding Tuberculosis in Emerging Economies
  • High-Cost Factor Associated With the Treatment of Tuberculosis May Hamper the Global Tuberculosis Treatment Drugs market.

Opportunities
  • Extensive Awareness Campaigns and Initiatives by Various Governments to Curb the Risk of Tuberculosis

Challenges
  • Inability to Identify the Initial Symptoms of Tuberculosis




The market is fragmented by numerous players. R&D, M&A, product launch are the key strategy adopted in the global tuberculosis diagnosis and treatment market. These players are collaborating with each other for the growth and improvement of the Tuberculosis Drugs market. For instance, In 2017, Johnson & Johnson entered into a partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to accelerate the discovery of a novel treatment for tuberculosis.

Target Audience:
Tuberculosis Drugs Manufacturers, Traders/Retailers/Suppliers/Distributors, Government & Regulatory Agencies, Potential Investors, Health Care Facilities and Downstream Vendors

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Tuberculosis Drug market on the basis of product [First-line Anti-TB Drugs and Second-line Anti-TB Drugs] , application [Active TB and Latent TB], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Tuberculosis Drug market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Tuberculosis Drug industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Tuberculosis Drug market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • First-line Anti-TB Drugs
  • Second-line Anti-TB Drugs
By Application
  • Active TB
  • Latent TB
By End User
  • Hospital
  • Clinic
  • Durgstore

By Testing
  • TB skin test (TST)
  • TB blood tests
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Tuberculosis
      • 3.2.2. Government Initiatives to Control the Proliferation of Tuberculosis
    • 3.3. Market Challenges
      • 3.3.1. Inability to Identify the Initial Symptoms of Tuberculosis
    • 3.4. Market Trends
      • 3.4.1. Increasing Government and Non-government Initiatives i.e. DOTS to Eradicate Tuberculosis
      • 3.4.2. Promising Pipeline for the Treatment of Tuberculosis.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tuberculosis Drug, by Type, Application, End User, Testing and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Tuberculosis Drug (Value)
      • 5.2.1. Global Tuberculosis Drug by: Type (Value)
        • 5.2.1.1. First-line Anti-TB Drugs
        • 5.2.1.2. Second-line Anti-TB Drugs
      • 5.2.2. Global Tuberculosis Drug by: Application (Value)
        • 5.2.2.1. Active TB
        • 5.2.2.2. Latent TB
      • 5.2.3. Global Tuberculosis Drug by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinic
        • 5.2.3.3. Durgstore
      • 5.2.4. Global Tuberculosis Drug by: Testing (Value)
        • 5.2.4.1. TB skin test (TST)
        • 5.2.4.2. TB blood tests
        • 5.2.4.3. Others
      • 5.2.5. Global Tuberculosis Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Tuberculosis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lupin Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Labatec Pharma SA (Jordan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sandoz S.A (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Macleods Pharmaceuticals (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Otsuka Pharmaceutical Co.Ltd. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Tuberculosis Drug Sale, by Type, Application, End User, Testing and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Tuberculosis Drug (Value)
      • 7.2.1. Global Tuberculosis Drug by: Type (Value)
        • 7.2.1.1. First-line Anti-TB Drugs
        • 7.2.1.2. Second-line Anti-TB Drugs
      • 7.2.2. Global Tuberculosis Drug by: Application (Value)
        • 7.2.2.1. Active TB
        • 7.2.2.2. Latent TB
      • 7.2.3. Global Tuberculosis Drug by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinic
        • 7.2.3.3. Durgstore
      • 7.2.4. Global Tuberculosis Drug by: Testing (Value)
        • 7.2.4.1. TB skin test (TST)
        • 7.2.4.2. TB blood tests
        • 7.2.4.3. Others
      • 7.2.5. Global Tuberculosis Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tuberculosis Drug: by Type(USD Million)
  • Table 2. Tuberculosis Drug First-line Anti-TB Drugs , by Region USD Million (2015-2020)
  • Table 3. Tuberculosis Drug Second-line Anti-TB Drugs , by Region USD Million (2015-2020)
  • Table 4. Tuberculosis Drug: by Application(USD Million)
  • Table 5. Tuberculosis Drug Active TB , by Region USD Million (2015-2020)
  • Table 6. Tuberculosis Drug Latent TB , by Region USD Million (2015-2020)
  • Table 7. Tuberculosis Drug: by End User(USD Million)
  • Table 8. Tuberculosis Drug Hospital , by Region USD Million (2015-2020)
  • Table 9. Tuberculosis Drug Clinic , by Region USD Million (2015-2020)
  • Table 10. Tuberculosis Drug Durgstore , by Region USD Million (2015-2020)
  • Table 11. Tuberculosis Drug: by Testing(USD Million)
  • Table 12. Tuberculosis Drug TB skin test (TST) , by Region USD Million (2015-2020)
  • Table 13. Tuberculosis Drug TB blood tests , by Region USD Million (2015-2020)
  • Table 14. Tuberculosis Drug Others , by Region USD Million (2015-2020)
  • Table 15. South America Tuberculosis Drug, by Country USD Million (2015-2020)
  • Table 16. South America Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 17. South America Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 18. South America Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 19. South America Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 20. Brazil Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 21. Brazil Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 22. Brazil Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 23. Brazil Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 24. Argentina Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 25. Argentina Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 26. Argentina Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 27. Argentina Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 28. Rest of South America Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 29. Rest of South America Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 31. Rest of South America Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 32. Asia Pacific Tuberculosis Drug, by Country USD Million (2015-2020)
  • Table 33. Asia Pacific Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 34. Asia Pacific Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 36. Asia Pacific Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 37. China Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 38. China Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 39. China Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 40. China Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 41. Japan Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 42. Japan Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 43. Japan Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 44. Japan Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 45. India Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 46. India Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 47. India Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 48. India Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 49. South Korea Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 50. South Korea Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 51. South Korea Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 52. South Korea Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 53. Taiwan Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 54. Taiwan Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 55. Taiwan Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 56. Taiwan Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 57. Australia Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 58. Australia Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 59. Australia Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 60. Australia Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 65. Europe Tuberculosis Drug, by Country USD Million (2015-2020)
  • Table 66. Europe Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 67. Europe Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 68. Europe Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 69. Europe Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 70. Germany Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 71. Germany Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 72. Germany Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 73. Germany Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 74. France Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 75. France Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 76. France Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 77. France Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 78. Italy Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 79. Italy Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 80. Italy Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 81. Italy Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 82. United Kingdom Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 83. United Kingdom Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 84. United Kingdom Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 85. United Kingdom Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 86. Netherlands Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 87. Netherlands Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 88. Netherlands Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 89. Netherlands Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 90. Rest of Europe Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 91. Rest of Europe Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 92. Rest of Europe Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 93. Rest of Europe Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 94. MEA Tuberculosis Drug, by Country USD Million (2015-2020)
  • Table 95. MEA Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 96. MEA Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 97. MEA Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 98. MEA Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 99. Middle East Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 100. Middle East Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 101. Middle East Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 102. Middle East Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 103. Africa Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 104. Africa Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 105. Africa Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 106. Africa Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 107. North America Tuberculosis Drug, by Country USD Million (2015-2020)
  • Table 108. North America Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 109. North America Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 110. North America Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 111. North America Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 112. United States Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 113. United States Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 114. United States Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 115. United States Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 116. Canada Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 117. Canada Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 118. Canada Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 119. Canada Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 120. Mexico Tuberculosis Drug, by Type USD Million (2015-2020)
  • Table 121. Mexico Tuberculosis Drug, by Application USD Million (2015-2020)
  • Table 122. Mexico Tuberculosis Drug, by End User USD Million (2015-2020)
  • Table 123. Mexico Tuberculosis Drug, by Testing USD Million (2015-2020)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Tuberculosis Drug: by Type(USD Million)
  • Table 136. Tuberculosis Drug First-line Anti-TB Drugs , by Region USD Million (2021-2026)
  • Table 137. Tuberculosis Drug Second-line Anti-TB Drugs , by Region USD Million (2021-2026)
  • Table 138. Tuberculosis Drug: by Application(USD Million)
  • Table 139. Tuberculosis Drug Active TB , by Region USD Million (2021-2026)
  • Table 140. Tuberculosis Drug Latent TB , by Region USD Million (2021-2026)
  • Table 141. Tuberculosis Drug: by End User(USD Million)
  • Table 142. Tuberculosis Drug Hospital , by Region USD Million (2021-2026)
  • Table 143. Tuberculosis Drug Clinic , by Region USD Million (2021-2026)
  • Table 144. Tuberculosis Drug Durgstore , by Region USD Million (2021-2026)
  • Table 145. Tuberculosis Drug: by Testing(USD Million)
  • Table 146. Tuberculosis Drug TB skin test (TST) , by Region USD Million (2021-2026)
  • Table 147. Tuberculosis Drug TB blood tests , by Region USD Million (2021-2026)
  • Table 148. Tuberculosis Drug Others , by Region USD Million (2021-2026)
  • Table 149. South America Tuberculosis Drug, by Country USD Million (2021-2026)
  • Table 150. South America Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 151. South America Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 152. South America Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 153. South America Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 154. Brazil Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 155. Brazil Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 156. Brazil Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 157. Brazil Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 158. Argentina Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 159. Argentina Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 160. Argentina Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 161. Argentina Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 162. Rest of South America Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 163. Rest of South America Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 164. Rest of South America Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 165. Rest of South America Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 166. Asia Pacific Tuberculosis Drug, by Country USD Million (2021-2026)
  • Table 167. Asia Pacific Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 168. Asia Pacific Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 169. Asia Pacific Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 170. Asia Pacific Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 171. China Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 172. China Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 173. China Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 174. China Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 175. Japan Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 176. Japan Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 177. Japan Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 178. Japan Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 179. India Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 180. India Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 181. India Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 182. India Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 183. South Korea Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 184. South Korea Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 185. South Korea Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 186. South Korea Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 187. Taiwan Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 188. Taiwan Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 189. Taiwan Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 190. Taiwan Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 191. Australia Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 192. Australia Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 193. Australia Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 194. Australia Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 195. Rest of Asia-Pacific Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 199. Europe Tuberculosis Drug, by Country USD Million (2021-2026)
  • Table 200. Europe Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 201. Europe Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 202. Europe Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 203. Europe Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 204. Germany Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 205. Germany Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 206. Germany Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 207. Germany Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 208. France Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 209. France Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 210. France Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 211. France Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 212. Italy Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 213. Italy Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 214. Italy Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 215. Italy Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 216. United Kingdom Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 217. United Kingdom Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 218. United Kingdom Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 219. United Kingdom Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 220. Netherlands Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 221. Netherlands Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 222. Netherlands Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 223. Netherlands Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 224. Rest of Europe Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 225. Rest of Europe Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 226. Rest of Europe Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 227. Rest of Europe Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 228. MEA Tuberculosis Drug, by Country USD Million (2021-2026)
  • Table 229. MEA Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 230. MEA Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 231. MEA Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 232. MEA Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 233. Middle East Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 234. Middle East Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 235. Middle East Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 236. Middle East Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 237. Africa Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 238. Africa Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 239. Africa Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 240. Africa Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 241. North America Tuberculosis Drug, by Country USD Million (2021-2026)
  • Table 242. North America Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 243. North America Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 244. North America Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 245. North America Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 246. United States Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 247. United States Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 248. United States Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 249. United States Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 250. Canada Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 251. Canada Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 252. Canada Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 253. Canada Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 254. Mexico Tuberculosis Drug, by Type USD Million (2021-2026)
  • Table 255. Mexico Tuberculosis Drug, by Application USD Million (2021-2026)
  • Table 256. Mexico Tuberculosis Drug, by End User USD Million (2021-2026)
  • Table 257. Mexico Tuberculosis Drug, by Testing USD Million (2021-2026)
  • Table 258. Research Programs/Design for This Report
  • Table 259. Key Data Information from Secondary Sources
  • Table 260. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tuberculosis Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Tuberculosis Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Tuberculosis Drug: by End User USD Million (2015-2020)
  • Figure 7. Global Tuberculosis Drug: by Testing USD Million (2015-2020)
  • Figure 8. South America Tuberculosis Drug Share (%), by Country
  • Figure 9. Asia Pacific Tuberculosis Drug Share (%), by Country
  • Figure 10. Europe Tuberculosis Drug Share (%), by Country
  • Figure 11. MEA Tuberculosis Drug Share (%), by Country
  • Figure 12. North America Tuberculosis Drug Share (%), by Country
  • Figure 13. Global Tuberculosis Drug share by Players 2020 (%)
  • Figure 14. Global Tuberculosis Drug share by Players (Top 3) 2020(%)
  • Figure 15. Global Tuberculosis Drug share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 18. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 19. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 20. Lupin Limited (India) Revenue: by Geography 2020
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 25. Labatec Pharma SA (Jordan) Revenue, Net Income and Gross profit
  • Figure 26. Labatec Pharma SA (Jordan) Revenue: by Geography 2020
  • Figure 27. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 28. Mylan N.V (United States) Revenue: by Geography 2020
  • Figure 29. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi S.A (France) Revenue: by Geography 2020
  • Figure 31. Sandoz S.A (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Sandoz S.A (Germany) Revenue: by Geography 2020
  • Figure 33. Novartis International AG (India) Revenue, Net Income and Gross profit
  • Figure 34. Novartis International AG (India) Revenue: by Geography 2020
  • Figure 35. Macleods Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 36. Macleods Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 37. Otsuka Pharmaceutical Co.Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Otsuka Pharmaceutical Co.Ltd. (Japan) Revenue: by Geography 2020
  • Figure 39. Global Tuberculosis Drug: by Type USD Million (2021-2026)
  • Figure 40. Global Tuberculosis Drug: by Application USD Million (2021-2026)
  • Figure 41. Global Tuberculosis Drug: by End User USD Million (2021-2026)
  • Figure 42. Global Tuberculosis Drug: by Testing USD Million (2021-2026)
  • Figure 43. South America Tuberculosis Drug Share (%), by Country
  • Figure 44. Asia Pacific Tuberculosis Drug Share (%), by Country
  • Figure 45. Europe Tuberculosis Drug Share (%), by Country
  • Figure 46. MEA Tuberculosis Drug Share (%), by Country
  • Figure 47. North America Tuberculosis Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Johnson & Johnson (United States)
  • Lupin Limited (India)
  • Pfizer Inc. (United States)
  • Eli Lilly and Company (United States)
  • Labatec Pharma SA (Jordan)
  • Mylan N.V (United States)
  • Sanofi S.A (France)
  • Sandoz S.A (Germany)
  • Novartis International AG (India)
  • Macleods Pharmaceuticals (India)
  • Otsuka Pharmaceutical Co.Ltd. (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation